Medicine
Omniscan 2870 mg/10 mL injection
Omniscan 2870 mg/10 mL injection is a prescription medicine containing Gadodiamide for intravenous use, marketed by GE Healthcare, with its source record on the US FDA register. It is available on request for export supply from India to licensed hospitals, importers and physicians.
Availability
Export supply from India to licensed buyers
Typical lead time
On request
Counted from payment and complete documents
Shipping
Ambient
Store OMNISCAN at controlled room temperature 20° to 25°C (68° to 77°F)…
Key facts
- Active ingredient (INN)
- Gadodiamide
- Brand
- Omniscan
- Strength
- 2870 mg/10 mL
- Dosage form
- Injection
- Route
- Intravenous
- Packs
- 10 vials of 10 mL
- Marketing authorisation holder
- GE Healthcare
- Manufacturer
- GE Healthcare
- Origin register
- US FDA, United States
- Storage
- Store OMNISCAN at controlled room temperature 20° to 25°C (68° to 77°F), excursions permitted to 15° to 30°C (59° to 86°F).
- Cold chain
- Not required on record
- Prescription status
- Prescription only
- Controlled substance
- Not recorded as controlled
- HS code (indicative)
- 3004.90Indicative only. Your customs broker confirms the final tariff code.
- Marketing category
- marketed
- Marketed since
- 19 April 2002
- Identifiers
- DailyMed set ID 1e9a37e2-f28a-4373-bf0f-3e9b60f42d8aNDC 0407-0690Application NDA020123
Record updated 12 November 2026
Documents available
Documents that can be provided with this medicine. Your regulator may ask for more, and the quote lists the full set.
No document list is recorded for this medicine yet. Tell us which documents your regulator needs (for example a CoA, COPP or GMP certificate) when you request a quote.
Packs
| Pack | Code | Labeler | Marketed since |
|---|---|---|---|
| 10 vial in 1 box / 10 mL in 1 vial | 0407-0690-10 | GE Healthcare | 19 April 2002 |
Status by register
Where this medicine is registered, from the source record and the regulator data we hold. Ask us about a country that is not listed.
| Register | Status | Source |
|---|---|---|
| US FDA | Listed, marketed | Source record for this pageChecked 12 November 2026 |
| US FDA | First approved 8 January 1993 | Drugs@FDA |
| EU (EMA) | Not recorded | — |
| India (CDSCO) | Not yet confirmed against CDSCO approval lists | — |
| United States | Registered | US FDA (NDC directory, openFDA)Checked 12 November 2026 |
Import route
Pick the destination country to see the legal import route, who applies and typical timelines, from our import guide for that country.
Import guides are available for 25 countries. Pick one to see its route summary.
BrazilColombiaEgyptEthiopiaGhanaIraqKazakhstanKenyaAll import guides
Other strengths and forms of Gadodiamide
Clinical summary
Gadodiamide is a paramagnetic contrast agent indicated for intravenous use to visualize lesions with abnormal vascularity in the brain, spine, and associated tissues, among other approved uses. It is available as injection for intravenous use. MedsAcross supplies Gadodiamide for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
Read about GadodiamideFor healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
Data sources
- DailyMed label record · Checked 12 November 2026
- OMNISCAN prescribing information (GE Healthcare) · U.S. National Library of Medicine, DailyMed
Need Omniscan 2870 mg/10 mL injection for your hospital or patient?
Send one request with the destination country and quantity. We confirm availability, lead time and the documents your regulator needs.